OSE Immunotherapeutics SA (EPA: OSE)
France flag France · Delayed Price · Currency is EUR
8.64
-0.01 (-0.12%)
Nov 21, 2024, 3:28 PM CET

OSE Immunotherapeutics Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Net Income
46.03-23-17.76-16.85-16.56-4.65
Upgrade
Depreciation & Amortization
-0.141.173.542.660.730.48
Upgrade
Other Amortization
3.532.36----
Upgrade
Stock-Based Compensation
1.311.752.732.941.791.51
Upgrade
Other Operating Activities
-0.13-0.98-3.380.64-2.323.24
Upgrade
Change in Income Taxes
3.41-0.22-0.24-0.33--
Upgrade
Change in Other Net Operating Assets
8.49-0.84-3.141.03-3.198.56
Upgrade
Operating Cash Flow
58.36-19.76-18.25-9.92-19.559.14
Upgrade
Operating Cash Flow Growth
-----748.19%
Upgrade
Capital Expenditures
-0.03-0.02-0.27-0.47-0.21-0.34
Upgrade
Investment in Securities
-54.940---2.9
Upgrade
Other Investing Activities
-0.54-0.490.3-0.36-0.29-0.18
Upgrade
Investing Cash Flow
-55.53-0.510.03-0.83-0.52.38
Upgrade
Long-Term Debt Issued
-5.0212.0615.286.965.63
Upgrade
Long-Term Debt Repaid
--3.36-1.8-0.59-0.81-0.71
Upgrade
Net Debt Issued (Repaid)
-3.371.6710.2614.696.154.92
Upgrade
Issuance of Common Stock
11.3911.66-0.2718.63-
Upgrade
Other Financing Activities
0-0.01--1.2-0.16
Upgrade
Financing Cash Flow
8.0113.3210.2714.9623.584.76
Upgrade
Miscellaneous Cash Flow Adjustments
--0----
Upgrade
Net Cash Flow
10.84-6.95-7.964.213.5316.27
Upgrade
Free Cash Flow
58.32-19.78-18.53-10.39-19.768.8
Upgrade
Free Cash Flow Growth
-----1717.98%
Upgrade
Free Cash Flow Margin
69.90%-888.19%-101.22%-39.50%-189.65%33.90%
Upgrade
Free Cash Flow Per Share
2.55-1.01-1.00-0.57-1.270.59
Upgrade
Cash Income Tax Paid
----0.050.07
Upgrade
Levered Free Cash Flow
40.61-11.18-9.07-4.21-12.479.38
Upgrade
Unlevered Free Cash Flow
42.44-9.8-8.21-3.69-12.39.49
Upgrade
Change in Net Working Capital
-3.870.983.06-0.753.23-8.4
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.